"Dana-Farber Brigham Cancer Center - Foxborough provides the latest medical oncology and hematology care to patients in Southern Massachusetts and parts of Rhode Island. The center makes it possible to offer the expertise and experience of New England's leading cancer center, while enabling patients to enjoy the comfort and convenience of staying close to home. Expert oncologists/hematologists and a specialized care team supported by Dana-Farber Brigham Cancer Center's vast clinical resources, offer patients the latest and most advanced treatments for cancer and blood disorders, including access to Dana-Farber's innovative clinical trials."

During the past decade, Dana-Farber Brigham Cancer Center - Foxborough conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana-Farber Brigham Cancer Center - Foxborough" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "MacroGenics" with 1 trials as a collaborator and "Translational Breast Cancer Research Consortium" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dana-Farber Brigham Cancer Center - Foxborough" are "Breast Cancer" (4 trials), "HER2-positive Breast Cancer" (3 trials), "HER2-negative Breast Cancer" (1 trials), "HR-Positive Breast Cancer" (1 trials) and "Hormone Receptor Positive Breast Cancer" (1 trials). Many other conditions were trialed in "Dana-Farber Brigham Cancer Center - Foxborough" in a lesser frequency.

Most popular intervention types in "Dana-Farber Brigham Cancer Center - Foxborough" are "Drug" (5 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (2 trials), "Pembrolizumab" (2 trials), "Sacituzumab Govitecan" (2 trials), "ADJUVANT ENDOCRINE THERAPY" (1 trials) and "Margetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana-Farber Brigham Cancer Center - Foxborough" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Dana-Farber Brigham Cancer Center - Foxborough". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Dana-Farber Brigham Cancer Center - Foxborough, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana-Farber Brigham Cancer Center - Foxborough, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".